US2016000798A1PendingUtilityA1
Uses of dpp iv inhibitors
Est. expiryMay 4, 2026(expired)· nominal 20-yr term from priority
A61P 9/06A61P 5/38A61P 9/00A61P 5/48A61P 5/50A61P 9/10A61P 43/00A61P 3/06A61P 9/14A61P 37/06A61P 9/12A61P 9/04A61P 3/04A61P 29/00A61P 3/10A61P 3/00A61P 19/02A61P 17/02A61P 15/00A61P 1/00A61K 31/522A61K 31/52A61K 31/5025A61K 31/155A61K 31/4184A61K 45/06A61K 31/7048A61K 31/197A61K 31/4985
60
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The specification describes the use of selected DPP IV inhibitors for the treatment of physiological functional disorders and for reducing the risk of the occurrence of such functional disorders in at-risk patient groups. In addition, the use of the above-mentioned DPP IV inhibitors in conjunction with other active substances is described, by means of which improved treatment outcomes can be achieved. These applications may be used to prepare corresponding medicaments.
Claims
exact text as granted — not AI-modified1 - 14 . (canceled)
15 . A method for treating diabetic foot or diabetes-associated ulcer, the method comprising administer a therapeutically effective amount of 1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine, or a salt thereof, to a patient in need thereof.Join the waitlist — get patent alerts
Track US2016000798A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.